2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

Colossal Biosciences, which has brought to life a small pack of genetically modified dire wolves, has acquired cloning ...

The apparel industry accounts for 10% of greenhouse gas emissions. Biotechs are working on reengineering natural products to make more sustainable textiles, which are gaining traction.

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Portfolio manager Eden Rahim sees biotech entering a new bull market amid lower rates, better trial data and renewed investor ...

Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in October 2025.